Status: Recruiting
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Participants needed: 203
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Phanes TherapeuticsUpdated: Jul 15, 2026Locations: 15
Eligibility criteria
18 years or older and able to sign informed consent and comply with the protocol... [+12]
Women who are pregnant or lactating. [+2]